Advancements in orthobiologics have effects across all market segments. We asked Andy Carter, Ph.D., Chief Technology Officer at TheraCell, to give his insight on the orthobiologics market—as it stands now, and where it’s heading tomorrow.
® 2019, surgeons were clear: they are interested in leveraging innovations in materials, robotics, AI and wearables for the benefit of their patients and their practices. They will look to the data to measure progress.
This month's articles on value analysis, biologic development and device distribution brought to mind last year's discussion with Patrick Sweeney, M.D. Revisit the diverse interests of this surgeon inventor.